Lall Dorothy, Cason E, Pasquel F J, Ali M K, Narayan K M V
a Institute of Public Health , Bengaluru , India.
b Rollins School of Public Health , Emory University , Atlanta , Georgia , USA.
COPD. 2016;13(1):93-9. doi: 10.3109/15412555.2015.1043518. Epub 2015 Sep 29.
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death globally. In addition to the mortality associated with it, people with COPD experience significant morbidity, making this set of conditions a major public health concern. Infections caused by influenza virus are a preventable cause of morbidity and vaccination has been shown to be effective. The evidence of their benefit in persons with COPD mainly comes from high-income countries where influenza vaccination is used in routine practice, but little is known about the effectiveness, cost-effectiveness, and scalability of vaccination in low- and middle-income countries. We therefore systematically reviewed and present evidence related to vaccination against influenza in persons with COPD with a special focus on studies from low- and middle-income countries (LMICs). Available data from 19 studies suggest that the use of influenza vaccine in persons with COPD is beneficial, cost-effective, and may be relevant for low- and middle-income countries. Wider implementation of this intervention needs to take into account the health care delivery systems of LMICs and use of prevalent viral strains in vaccines to be most cost effective.
慢性阻塞性肺疾病（COPD）是全球主要死因之一。除了与之相关的死亡率外，COPD患者还会经历严重的发病情况，这使得这一系列病症成为一个重大的公共卫生问题。流感病毒引起的感染是一种可预防的发病原因，且疫苗接种已被证明是有效的。其对COPD患者有益的证据主要来自高收入国家，在这些国家流感疫苗用于常规医疗，但对于低收入和中等收入国家疫苗接种的有效性、成本效益和可扩展性知之甚少。因此，我们系统地回顾并呈现了与COPD患者流感疫苗接种相关的证据，特别关注来自低收入和中等收入国家（LMICs）的研究。来自19项研究的现有数据表明，COPD患者使用流感疫苗是有益的、具有成本效益的，并且可能适用于低收入和中等收入国家。要更广泛地实施这一干预措施，需要考虑低收入和中等收入国家的医疗保健提供系统，并在疫苗中使用流行病毒株，以实现最高的成本效益。
